Octapharma Aims to Expand U.S. Immune Globulin Therapy...(a's IGIV product Forward-looking ...)

Date:9/23/2009

a's IGIV product, octagam(R) (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human) is indicated for the restoration and maintenance of circulating blood volume. Octapharma employs over 3,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration, providing the highest level of production flexibility and minimizing product shortages. For more information, please visit www.octapharma.com.

Forward-looking statements

This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.

'/>"/>

SOURCE Octapharma AG Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
2. Octapharma USA Retains Yankee Public Relations as its Agency of Record
3. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
4. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
5. Octapharma Joins Biotechnology Industry Organization
6. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
7. DIA/FDA/PhRMA Conference To Expand The Role Of Modeling And Simulation In Clinical Drug Development
8. Medelis Expands CRO Services to Medical Devices, Appoints Dr. Inder Makin as VP
9. PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says
10. Toshos Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I.V. Automation Strategic Partnership
11. OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners